Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI

NEKTAR THERAPEUTICS

2025-Q3 EPS reported -$8.14 revenue$33,425,000

Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.
Revenue $11.8M, down from $24.1M YoY due to sale of Huntsville facility in Dec 2024.
Cash & marketable securities $270.2M as of Sep 30, 2025; includes $107.2M from July secondary offering.
R&D expense $27.3M vs $35.0M YoY; focus on rezpegaldesleukin, NKTR-0165, NKTR-422.
FDA granted Fast Track for rezpegaldesleukin in severe alopecia areata; topline data expected Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.